PD-L1 expression in gastric carcinoma – a biomarker for immunotherapy


  • Dhanya Menon
  • Ganthimathy Sekhar




PD-L1, gastric cancer, checkpoint inhibitor, immunotherapy


Introduction and Aim: Immunotherapy is now being widely used for targeted therapy in several cancers. The PD-1/ PD-L1 (programmed cell death receptor/programmed cell death ligand) axis inhibits the expansion of tumour specific T cells and prevents the immune response against tumours. PD-L1 expression is seen in many cancers including gastric carcinomas and anti PDL1 antibodies are being used to produce tumour regression. This study was done to evaluate PD-L1 expression in gastric carcinomas and correlate this with the different histological types, grades and stages of these tumours


Materials and Methods: In this study, 50 cases of gastric adenocarcinoma were analysed for PD-L1 expression using immunohistochemistry. PD-L1 expression was correlated with histopathological factors including histological type, differentiation, grade and stage using statistical methods.


Results: A positive PD-L1 expression was observed in 52% of the cases. A positive correlation between PD-L1 positivity and tumour depth to which the tumour was invading the stomach was observed. No correlation was noted with expression of PD-L1 and histological type, differentiation, histological grade and presence/absence of nodal metastasis.


Conclusion: PD-L1 expression was seen in more than half of the patients in our study. Hence it is suggested that anti PD-L1 inhibitors can be used as an adjunct in the treatment of gastric cancers, especially those with a greater depth of invasion.

Author Biographies

Dhanya Menon

Department of Pathology, Saveetha Medical College and Hospital, Saveetha Nagar, Thandalam, Chennai 602105, Tamil Nadu, India

Ganthimathy Sekhar

Department of Pathology, Saveetha Medical College and Hospital, Saveetha Nagar, Thandalam, Chennai 602105, Tamil Nadu, India


Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A., Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer Journal for Clinicians. 2018 Nov;68(6):394-424.

Etemadi, A., Safiri, S., Sepanlou, S.G., Ikuta, K., Bisignano, C., Shakeri, R., et al., The global, regional, and national burden of stomach cancer in 195 countries, 1990–2017: a systematic analysis for the Global Burden of Disease study 2017. The Lancet gastroenterology & hepatology. 2020 Jan 1;5(1):42-54.

Nandi, A., Biswas, P.K., Kar, M., Sinha, S.K. Clinicopathological profile of gastric cancer in a tertiary care hospital in Eastern India: a prospective 2 year study. Clinical Cancer Investigation Journal. 2014 Jan 1;3(1):14.

Yang, L., Wang, Y., Wang, H. Use of immunotherapy in the treatment of gastric cancer. Oncology Letters. 2019 Dec 1;18(6):5681-5690.

Abozeid, M., Rosato, A., Sommaggio, R. Immunotherapeutic strategies for gastric carcinoma: A review of preclinical and clinical recent development. BioMed Research International. 2017 Jan 1;2017. Article ID 5791262

Rangel-Sosa, M.M., Aguilar-Córdova, E., Rojas-Martínez, A. Immunotherapy and gene therapy as novel treatments for cancer. Colombia Médica. 2017 Sep;48(3):138-147.

Waldman, A.D., Fritz, J.M., Lenardo, M.J. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nature Reviews Immunology. 2020 20:1-8.

Khalil, D.N., Smith, E.L., Brentjens, R.J., Wolchok, J.D. The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol.2016;13:273-290.

Papaioannou, N.E., Beniata, O.V., Vitsos, P., Tsitsilonis, O., Samara, P. Harnessing the immune system to improve cancer therapy. Ann Transl Med. 2016;4:261

Robert, C., Schachter, J., Long, G.V., Arance, A., Grob, J.J., Mortier, L., et al., Pembrolizumab versus ipilimumab in advanced melanoma. New England Journal of Medicine. 2015 Jun 25;372(26):2521-32.

Lynch, D., Murphy, A. The emerging role of immunotherapy in colorectal cancer. Ann Transl Med. 2016;4(16) :1-14.

Pardol, D.M. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2016;12(4):252 -264.

Kwon, M.J., Kim, K.C., Nam, E.S., Cho, S.J., Park, H.R., Min, S.K., et al., Programmed death ligand-1 and MET co-expression is a poor prognostic factor in gastric cancers after resection. Oncotarget. 2017;8(47):82399.

Kulangara, K., Hanks, D.A., Waldroup, S., Peltz, L., Shah, S., Roach, C., et al., Development of the combined positive score (CPS) for the evaluation of PD-L1 in solid tumors with the immunohistochemistry assay PD-L1 IHC 22C3 pharmDx. Journal of Clinical Oncology. 2017; 35(15).

Kulangara, K., Zhang, N., Corigliano, E., Guerrero, L., Waldroup, S., Jaiswal, D., et al., Clinical utility of the combined positive score for programmed death ligand-1 expression and the approval of pembrolizumab for treatment of gastric cancer. Archives of pathology & laboratory medicine. 2019;143(3):330-337.

Mokhtari, R.B., Homayouni, T.S., Baluch, N., Morgatskaya, E., Kumar, S., Das, B., et al., Combination therapy in combating cancer. Oncotarget. 2017;8(23):38022.

Kim, J.H., Kim, S.Y., Shin, E.Y., Jung, J.H., Choi, H.J., Jun, K.H. Expression patterns of programmed death 1 and programmed death 1 ligand 1 on T cells in gastric cancer. Oncology letters. 2019;18(3):2661-2669.

Park, Y., Koh, J., Na, H.Y., Kwak, Y., Lee, K.W., Ahn, S.H., et al., PD-L1 testing in gastric cancer by the combined positive score of the 22C3 PharmDx and SP263 assay with clinically relevant cut-offs. Cancer Research and Treatment: Official Journal of Korean Cancer Association. 2020;52(3):661.

Ilie, M., Long-Mira, E., Bence, C., Butori, C., Lassalle, S., Bouhlel, L., et al., Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies. Annals of Oncology. 2016;27(1):147-153.

Liu, X., Choi, M.G., Kim, K., Kim, K.M., Kim, S.T., Park, S.H., et al., High PD-L1 expression in gastric cancer (GC) patients and correlation with molecular features. Pathology-Research and Practice. 2020;216(4):152881.

Huang, K.H., Chen, M.H., Fang, W.L., Lin, C.H., Chao, Y., Lo, S.S., et al., The clinicopathological characteristics and genetic alterations of signet-ring cell carcinoma in gastric cancer. Cancers. 2020;12(8):2318.

Chen, M.H., Fang, W.L., Hung, Y.P., Chao, Y. Mucinous gastric adenocarcinoma: A good candidate for immune therapy?. Journal of the Chinese Medical Association. 2020;83(7):624-625.

Gu, L., Chen, M., Guo, D., Zhu, H., Zhang, W., Pan, J., et al., PD-L1 and gastric cancer prognosis: A systematic review and meta-analysis. PloS one. 2017;12(8):e0182692.

Yamashita, K., Iwatsuki, M., Harada, K., Eto, K., Hiyoshi, Y., Ishimoto, T., et al., Prognostic impacts of the combined positive score and the Tumour proportion score for programmed death ligand?1 expression by double immunohistochemical staining in patients with advanced gastric cancer. Gastric Cancer. 2020;23:95-104.

Eto, S., Yoshikawa, K., Nishi, M., Higashijima, J, Tokunaga T, Nakao T, et al., Programmed cell death protein 1 expression is an independent prognostic factor in gastric cancer after curative resection. Gastric cancer. 2016;19(2):466-471.




How to Cite

Menon D, Sekhar G. PD-L1 expression in gastric carcinoma – a biomarker for immunotherapy. Biomedicine [Internet]. 2022 May 1 [cited 2022 Nov. 27];42(2):383-7. Available from: https://biomedicineonline.org/home/article/view/707



Original Research Articles

Plum Analytics